首页> 外文期刊>Bone marrow transplantation >Recurrence of beta-thalassemia major more than 20 years after HLA-identical sibling BMT treated successfully with donor lymphocyte infusion.
【24h】

Recurrence of beta-thalassemia major more than 20 years after HLA-identical sibling BMT treated successfully with donor lymphocyte infusion.

机译:在使用供体淋巴细胞输注成功治疗了HLA相同的同胞BMT后,β-地中海贫血的严重复发已超过20年。

获取原文
获取原文并翻译 | 示例
       

摘要

Allogeneic BMT remains the only curative treatment for major P-thalassemia. Early graft failure and persistent mixed chimerism are not uncommon after BMT, but late recurrence of P-thalassemia is rare, with only a few cases having been treated successfully with a second transplant. Although donor lymphocyte infusion (DLI) is an effective treatment for late recurrence of some hematological malignancies after allogeneic BMT, DLI has only been reported in few cases for early graft failure in thalassemia.We report a case of late recurrent P-thalassemia major successfully treated with DLI 23 years after BMT. The patient signed institutional review board-approved consent to allow his medical records to be used for research. A 2.5-year-old boy received BMT from his HLA-identical ABO-mismatched sister with beta-thalassemia minor after conditioning with BU (14mg/kg) and CY (200mg/kg).
机译:异基因BMT仍然是重度P地中海贫血的唯一治疗方法。 BMT后早期移植失败和持续的混合嵌合现象并不罕见,但P地中海贫血的晚期复发很少见,只有少数病例第二次移植成功治疗。尽管供体淋巴细胞输注(DLI)对于异基因BMT后某些血液系统恶性肿瘤的晚期复发是一种有效的治疗方法,但仅在少数发生地中海贫血移植失败的病例中报道了DLI。我们报道了一例成功治疗的晚期复发性P地中海贫血病例。在BMT之后的23年与DLI合作。患者签署了机构审查委员会批准的同意书,以便将其病历用于研究。一个2.5岁的男孩在接受BU(14mg / kg)和CY(200mg / kg)调节后,从HLA相同的ABO不匹配姐姐那里接受了BMT治疗,并伴有轻微的β地中海贫血。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号